MMRF Patient Webinar:
Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Currently, induction therapy followed by high-dose melphalan (HDM) and ASCT is the standard of care for the majority of patients with newly diagnosed multiple myeloma. ASCT can provide long and deep remissions (that is, periods in which there are no symptoms of myeloma or signs that any abnormal plasma cells are present). In this webinar, you will learn about how ASCT is used in multiple myeloma treatment. Participants will learn who is eligible for this procedure, how stem cells are collected and stored, what steps are involved, and what to expect in the recovery process.